Rarity Bioscience AB - Radically improving cancer diagnostics

Rarity BioScience has developed an ultrasensitive and multiplex technology for mutation detection in liquid biopsies, meaning that we can detect down to 1 mutation in 100,000 healthy cells, which is up to 100 times more sensitive than current technology. And perhaps the best part, the assays are run using existing instruments already available in every hematology lab.We provide the sensitive and cost efficient tools needed to replace conventional costly and painful tissue biopsies with blood samples to enable early detection of cancer relapse and treatment response.Rarity is funded by seasoned Uppsala entrepreneurs and researchers, combining previously successful technologies in an ingenious and beautiful way.